Results of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus® tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy.

Strahlenther Onkol. 2021 Jan;197(1):63-73.

Více informací ZDE 

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.

Lancet Oncol. 2021 Jan;22(1):29-42.

Více informací ZDE 

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.

Eur J Cancer. 2021 Jan;143:64-74.

Více informací ZDE 

Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results.

Radiother Oncol. 2021 Jan;154:214-219.

Více informací ZDE 

ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.

J Clin Oncol. 2021 Jan 1;39(1):38-47.

Více informací ZDE 

Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.

J Clin Oncol. 2021 Jan 1;39(1):17-29.

Více informací ZDE 

Topical Betamethasone Valerate As a Prophylactic Agent to Prevent Acute Radiation Dermatitis in Head and Neck Malignancies: A Randomized, Open-Label, Phase 3 Trial.

Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):151-160.

Více informací ZDE 

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

Lancet Oncol. 2021 Feb;22(2):223-234.

Více informací ZDE 

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.

Lancet Oncol. 2021 Feb;22(2):235-245.

Více informací ZDE 

Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.

Lancet Oncol. 2021 Mar;22(3):381-390.

Více informací ZDE 

4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.

Lancet Oncol. 2021 Mar;22(3):332-340.

Více informací ZDE 

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.

J Clin Oncol. 2021 Mar 1;39(7):787-796.

Více informací ZDE 

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.

Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):975-986.

Více informací ZDE 

Breast-Conserving Surgery Followed by Partial or Whole Breast Irradiation: Twenty-Year Results of a Phase 3 Clinical Study.

Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):998-1006.

Více informací ZDE 

Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial.

J Clin Oncol. 2021 Apr 1;39(10):1098-1107.

Více informací ZDE 

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

JAMA Oncol. 2021 Apr 1;7(4):555-563.

Více informací ZDE 

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

Lancet Oncol. 2021 Apr;22(4):476-488.

Více informací ZDE 

IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study.

Breast Cancer Res. 2021 Apr 13;23(1):46.

Více informací ZDE 

Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.

Lancet Gastroenterol Hepatol. 2021 Apr;6(4):292-303.

Více informací ZDE 

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.

J Clin Oncol. 2021 Apr 10;39(11):1234-1242.

Více informací ZDE 

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

N Engl J Med. 2021 Apr 1;384(13):1191-1203.

Více informací ZDE 

Once Daily Versus Twice Daily External Beam Accelerated Partial Breast Irradiation: A Randomized Prospective Study.

Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1296-1300.

Více informací ZDE 

Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial).

Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1311-1324.

Více informací ZDE 

Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial.

Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1368-1376.

Více informací ZDE 

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Lancet Oncol. 2021 Apr;22(4):450-462.

Více informací ZDE 

Two-year toxicity of simultaneous integrated boost in hypofractionated prone breast cancer irradiation: Comparison with sequential boost in a randomized trial.

Radiother Oncol. 2021 May;158:62-66.

Více informací ZDE 

Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial).

Radiother Oncol. 2021 May;158:268-275.

Více informací ZDE 

Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.

Lancet Oncol. 2021 May;22(5):716-726.

Více informací ZDE 

Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.

Eur Urol. 2021 May;79(5):595-604.

Více informací ZDE 

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol. 2021 May;22(5):702-715.

Více informací ZDE 

Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.

Lancet Oncol. 2021 May;22(5):597-608.

Více informací ZDE 

Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).

J Thorac Oncol. 2021 May;16(5):840-849.

Více informací ZDE 

Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.

J Clin Oncol. 2021 Jun 20;39(18):2025-2036.

Více informací ZDE 

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.

J Clin Oncol. 2021 Jun 20;39(18):1995-2004.

Více informací ZDE 

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

Lancet Oncol. 2021 Jun;22(6):813-823.

Více informací ZDE 

1